Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.

ABSTRACT:

Background

The use of somatostatin analogues (SSAs) has not been formally approved in pulmonary neuroendocrine tumours (NETs) in the absence of positive controlled trials, even though it is recommended as a potential therapeutic option in recent guidelines.

Patients and methods

We have assessed the use of SSA in the general practice in Austria by retrospectively analysing patients with pulmonary NETs referred to our European Neuroendocrine Tumor Society centre in Vienna for second opinion or further therapy. In addition, we have analysed the somatostatin receptor (SSTR) expression of those patients by immunohistochemistry (IHC) and SSTR imaging, e.g. ⁶⁸Ga-DOTANOC-positron emission tomography/computed tomography, and whether such analyses had been carried out befor

SUBMITTER: Kiesewetter B 

PROVIDER: S-EPMC9271480 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature